CeriBell (NASDAQ:CBLL) VP David Foehr Sells 4,560 Shares

by · The Cerbat Gem

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) VP David Foehr sold 4,560 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total transaction of $81,168.00. Following the sale, the vice president owned 17,550 shares in the company, valued at $312,390. The trade was a 20.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Foehr also recently made the following trade(s):

  • On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The stock was sold at an average price of $19.98, for a total value of $15,604.38.
  • On Monday, February 23rd, David Foehr sold 569 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total value of $11,260.51.
  • On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $20.00, for a total value of $111,120.00.
  • On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total value of $125,565.60.

CeriBell Price Performance

NASDAQ CBLL traded down $0.36 during trading hours on Friday, reaching $17.53. The company’s stock had a trading volume of 143,263 shares, compared to its average volume of 346,921. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $24.33. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $659.83 million, a price-to-earnings ratio of -11.93 and a beta of 1.12. The firm’s 50-day moving average price is $20.84 and its 200-day moving average price is $16.42.

CeriBell (NASDAQ:CBLL – Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The business had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. On average, equities research analysts predict that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Several institutional investors have recently modified their holdings of CBLL. Russell Investments Group Ltd. raised its stake in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after acquiring an additional 854 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the last quarter. Deutsche Bank AG raised its position in CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after purchasing an additional 1,393 shares during the period. Finally, Royal Bank of Canada lifted its stake in CeriBell by 10.8% in the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after purchasing an additional 1,514 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have commented on CBLL shares. TD Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. BTIG Research reiterated a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Finally, Canaccord Genuity Group raised their price target on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

View Our Latest Research Report on CeriBell

CeriBell Company Profile

(Get Free Report)

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

See Also